Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 3Phase 2/3 1Phase 1 1

Status

Recruiting 13Completed 13Active not recruiting 7Unknown 5Not yet recruiting 4Terminated 3Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × lenvatinib × Clear all
NCT03867370 2023-11-29

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Terminated
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01133756 2023-06-22

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Eisai Inc.

Phase 1/2 Terminated
7 enrolled 6 charts
Gynecologic

Ovarian Neoplasms

NCT01433991 2021-06-08

A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Eisai Inc.

Phase 1/2 Terminated
30 enrolled 42 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡